Life Therapeutics (ASX: LFE) announced today that the company has started an early-stage project to develop a specialty immune globulin for influenza. This is a multi-year program to immunize selected donors with the flu vaccine and collect their hyperimmune blood plasma for use in a therapeutic drug to combat infection caused by the influenza virus.
Leading cell therapy company CyGenics Ltd. (ASX: CYN), today announced its intention to investigate the listing of its tissue banking business, predominantly held under its subsidiary, CordLife Pte Ltd, on a key Asian stock exchange.
CyGenics Limited (ASX: CYN) announced today that it has entered into a collaborative research agreement with the Johns Hopkins University School of Medicine (Johns Hopkins), a US world leader in research and education in medicine.
Biota (ASX: BTA) reported today that the French government has announced that it intends to increase its pandemic stockpile of Relenza from 200,000 units to 9 million units over the next two years 1.
Leading Australian health systems provider, Working Systems Solutions (ASX: WSS), today announced it had signed a contract with the Australian Stem Cell Centre Ltd (ASCC).
The board of Biotech Capital (ASX: BTC) announced that its investee company (Stem Cell Sciences plc ("SCS") has concluded an agreement with the US-Based company Lexicon Genetics ("Lexicon"). Lexicon is a biopharmaceutical company focused on the discovery and development of treatments for a range of human diseases primarily using its proprietary gene knock out technology.
Clinical Cell Culture Ltd (ASX: CCE) announced today that it has signed a Heads of Agreement with Sewon Cellontech Co. Ltd. (Cellontech - www.cellontech.com) for the local contract manufacturing of CellSpray(R) products for Korea. An investor conference call is scheduled, refer details below.
